Float Short %

13.21

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

EPS Last/This Y

-0.47

EPS This/Next Y

0.13

Price

3.41

Target Price

9.5

Analyst Recom

1.25

Performance Q

23.1

Relative Volume

0.53

Beta

1.92

Ticker: GOSS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	GOSS	2.47	0.13	0.00	157230
2025-11-11	GOSS	2.59	0.13	0.00	157646
2025-11-12	GOSS	2.69	0.13	0.01	157776
2025-11-13	GOSS	2.5	0.13	0.03	158300
2025-11-14	GOSS	2.7	0.13	0.04	158433
2025-11-17	GOSS	2.99	0.13	0.00	158264
2025-11-18	GOSS	3.09	0.13	0.10	157917
2025-11-19	GOSS	3.14	0.13	0.03	158268
2025-11-20	GOSS	3.11	0.13	0.02	159048
2025-11-21	GOSS	3.07	0.13	0.04	159320
2025-11-24	GOSS	3.19	0.17	0.02	126877
2025-11-25	GOSS	3.27	0.17	2.03	127324
2025-11-26	GOSS	3.35	0.20	0.13	130579
2025-12-01	GOSS	3.13	0.20	0.13	131292
2025-12-02	GOSS	2.98	0.20	0.25	131650
2025-12-03	GOSS	3.41	0.20	1.65	131659
2025-12-04	GOSS	3.33	0.24	5.10	137492
2025-12-05	GOSS	3.33	0.26	0.01	139554
2025-12-08	GOSS	3.42	0.26	0.00	139171
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	GOSS	2.48	-40.8	107.5	-0.70
2025-11-11	GOSS	2.59	-40.8	122.6	-0.70
2025-11-12	GOSS	2.69	-40.8	122.7	-0.70
2025-11-13	GOSS	2.51	-40.8	125.3	-0.70
2025-11-14	GOSS	2.70	-23.3	121.8	-0.71
2025-11-17	GOSS	2.99	-28.9	121.2	-0.72
2025-11-18	GOSS	3.04	-28.9	123.3	-0.71
2025-11-19	GOSS	3.14	-28.9	122.9	-0.71
2025-11-20	GOSS	3.10	-28.9	123.9	-0.72
2025-11-21	GOSS	3.06	-27.8	123.9	-0.72
2025-11-24	GOSS	3.19	-27.8	122.6	-0.72
2025-11-25	GOSS	3.27	-27.8	123.0	-0.72
2025-11-26	GOSS	3.35	-27.8	123.0	-0.72
2025-12-01	GOSS	3.13	-27.8	125.1	-0.72
2025-12-02	GOSS	2.99	-27.8	124.7	-0.72
2025-12-03	GOSS	3.42	-27.8	120.3	-0.72
2025-12-04	GOSS	3.32	-27.8	124.3	-0.72
2025-12-05	GOSS	3.33	-27.8	123.5	-0.72
2025-12-08	GOSS	3.41	-27.8	-	-0.72
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	GOSS	0.06	3.54	14.49
2025-11-11	GOSS	0.06	3.54	14.49
2025-11-12	GOSS	0.06	3.54	13.49
2025-11-13	GOSS	0.06	3.54	13.49
2025-11-14	GOSS	0.06	3.54	13.49
2025-11-17	GOSS	0.06	0.93	13.48
2025-11-18	GOSS	0.06	0.93	13.48
2025-11-19	GOSS	0.06	0.93	13.48
2025-11-20	GOSS	0.06	0.93	13.48
2025-11-21	GOSS	0.06	0.93	13.48
2025-11-24	GOSS	0.06	2.10	13.48
2025-11-25	GOSS	0.06	2.10	13.48
2025-11-26	GOSS	0.06	2.10	13.21
2025-12-01	GOSS	0.06	2.13	13.21
2025-12-02	GOSS	0.06	2.13	13.21
2025-12-03	GOSS	0.06	2.13	13.21
2025-12-04	GOSS	0.06	2.13	13.21
2025-12-05	GOSS	0.06	2.13	13.21
2025-12-08	GOSS	0.06	2.08	13.21
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.19

Avg. EPS Est. Next Quarter

-0.21

Insider Transactions

0.06

Institutional Transactions

2.08

Beta

1.92

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

77.6

Max Drawdown 5-Year %

-96.8

Target Price

9.5

P/E

Forward P/E

PEG

P/S

17.92

P/B

P/Free Cash Flow

EPS

-0.69

Average EPS Est. Cur. Y

-0.72

EPS Next Y. (Est.)

-0.59

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-354.5

Relative Volume

0.53

Return on Equity vs Sector %

162.8

Return on Equity vs Industry %

177.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

Gossamer Bio, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 144

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

stock quote shares GOSS – Gossamer Bio, Inc. Stock Price stock today

news today GOSS – Gossamer Bio, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch GOSS – Gossamer Bio, Inc. yahoo finance google finance

stock history GOSS – Gossamer Bio, Inc. invest stock market

stock prices GOSS premarket after hours

ticker GOSS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GOSS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y